Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Towards a Tailored Treatment of Chronic Lymphocytic Leukemia
share announcement

Towards a Tailored Treatment of Chronic Lymphocytic Leukemia

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 850

Special Issue Editors

Prof. Dr. Antonio Cuneo

E-Mail Website
Guest Editor
Hematology, Department of Medical Sciences, University of Ferrara, Via Ariosto, 35-44121 Ferarra, Italy
Interests: chronic lymphocytic leukemia and follicular lymphoma
Prof. Dr. Paolo Prospero Ghia

E-Mail Website
Guest Editor
Medical Oncology, Università Vita-Salute San Raffaele, Milan, Italy
Interests: chronic lymphocytic leukemia
Prof. Dr. Francesca Romana Mauro

E-Mail Website
Guest Editor
Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, 00161 Rome, Italy
Interests: chronic lymphoproliferative disorders
Special Issues, Collections and Topics in MDPI journals
Dr. Marta Coscia

E-Mail Website
Guest Editor
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, 10126 Torino, Italy
Interests: chronic lymphocytic leukemia; immunotherapy; CAR T cells
Prof. Dr. Gianluca Gaidano

E-Mail Website
Guest Editor
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy
Interests: lymphoma; chronic lymphocytic leukemia; prognosticators; predictors; investigational therapies

Special Issue Information

Dear Colleagues,

Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia, representing 1.1% of all cancer cases, with 18,740 new cases and 4,490 deaths for CLL in 2023 in the U.S. and an estimated 10-year prevalence of 49.8 people per 100,000 inhabitants in the UK. The modern treatment of CLL has dramatically changed thanks to the development of effective mechanism-driven drugs, which have been proven to be superior to chemoimmunotherapy, independent of age. Because the choice and management of treatment largely depend on both disease-related and patient-specific features, we set out to discuss and put into perspective (i) prognostic/predictive factors in the era of novel drugs, (ii) treatment sequencing, (iii) the monitoring of responses and resistance to treatment, (iv) the management of adverse events, and (v) innovative therapeutic options. This Special Issue will highlight the current state of the art of the tailored treatment of CLL in addition to future prospects for salvage treatment in patients refractory to BTK and BCL2 inhibitors.

Prof. Dr. Antonio Cuneo
Prof. Dr. Paolo Prospero Ghia
Prof. Dr. Francesca Romana Mauro
Dr. Marta Coscia
Prof. Dr. Gianluca Gaidano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic lymphocytic leukemia
  • treatment
  • targeted therapy
  • immunotherapy
  • adverse events
  • prognosis
  • resistance
  • MR

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 1155 KiB  
Review
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review
by Andrea Visentin, Sara Frazzetto, Livio Trentin and Annalisa Chiarenza
Cancers 2024, 16(7), 1290; https://doi.org/10.3390/cancers16071290 - 26 Mar 2024
Viewed by 502
Abstract
In the last few years, several agents targeting molecules that sustain the survival and the proliferation of chronic lymphocytic leukemia (CLL) cells have become clinically available. Most of these drugs target surface proteins, such as CD19 or CD20, via monoclonal or bispecific monoclonal [...] Read more.
In the last few years, several agents targeting molecules that sustain the survival and the proliferation of chronic lymphocytic leukemia (CLL) cells have become clinically available. Most of these drugs target surface proteins, such as CD19 or CD20, via monoclonal or bispecific monoclonal antibodies (BsAbs), CAR T cells, intracellular proteins like BTK by using covalent or non-covalent inhibitors or BCL2 with first or second generation BH3-mimetics. Since the management of CLL is evolving quickly, in this review we highlighted the most important innovative treatments including novel double and triple combination therapies, CAR T cells and BsAbs for CLL. Recently, a large number of studies on novel combinations and newer strategic options for CLL therapy have been published or presented at international conferences, which were summarized and linked together. Although the management of treatment with a single continuous agent is easier, the emergence of protein mutations, long-term toxicities and costs are important concerns that favor the use of a fixed duration therapy. In the future, a measurable residual disease (MRD)-guided treatment cessation and MRD-based re-initiation of targeted therapy seems to be a more feasible approach, allowing identification of the patients who might benefit from continuous therapy or who might need a consolidation with BsAbs or CAR T cells to clear the neoplastic clone. Full article
(This article belongs to the Special Issue Towards a Tailored Treatment of Chronic Lymphocytic Leukemia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop